Advertisement

Vergleich einer Standard-Chemotherapie (BVP) mit einem sequentiell alternierenden Therapieprotokoll (BVP/EIP) bei Patienten mit Hodentumoren und weit fortgeschrittener Metastasierung (“Bulky Disease”)

  • R. Kuzmits
  • H. Ludwig
  • P. Aiginger
Conference paper

Zusammenfassung

42 Patienten mit ausgedehnt metastasierten Hodentumoren (“bulky disease”) wurden entweder mit einem Standard-Chemotherapieprotokoll (BVP, 20 Patienten) oder sequentiell alternierend mit BVP/EIP (22 Patienten) behandelt. Alle Patienten waren chemotherapeutisch nicht vorbehandelt.

Mit der Standard-BVP-Therapie wurde bei 10 (50%) Patienten eine CR und bei einem eine PR/NED erzielt. Die sequentiell alternierende BVP/EIP-Therapie führte bei 16 (73%) Patienten zu einer CR, 4 Patienten erzielten eine PR/NED.

Das mediane follow-up der mit BVP-behandelten Patienten beträgt 44 Monate, wobei bisher 1 Rezidiv aufgetreten ist; derzeit befinden sich 10 (50%) Patienten in CR. Nach einer medianen Beobachtungszeit von 21 Monaten sind in der mit BVP/EIP behandelten Gruppe bisher 4 Rezidive aufgetreten, 16 (73%) Patienten befinden sich in CR oder PR/NED.

Die sequentiell alternierende BVP/EIP-Therapie scheint einer monophasischen BVP-Therapie überlegen zu sein und könnte bei Patienten mit Hodentumoren und “bulky disease” eine attraktive Form der Primärtherapie darstellen.

Abstract

42 patients with testicular cancer and “bulky disease” were treated with a standardchemotherapy (BVP, 20 patients) or with a sequential alternating therapy-protocol (BVP/EIP, 22 patients). All patients received no prior chemotherapy.

With the standard-BVP-therapy 10 (50%) patients reached a CR, one patient is in PR/NED. The sequential alternating BVP/EIP-therapy resulted in 16 (73%) patients in a CR, 4 patients reached a PR/NED.

The median follow-up of the BVP-treated patients is 44 months, and 1 relapse occured; 10 (50%) patients are in CR. After a median follow-up of 21 months 4 relapses were observed in the BVP/EIP-treated patients group, 16 (73%) patients are in CR or in PR/NED.

The sequential alternating BVP/EIP-therapy seems to be superior to a standard-BVP-chemotherapy and might represent an attractive form of therapy in patients with testicular cancer and “bulky disease”.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bonadonna G, Valagussa P, Santoro A (1986) Alternating noncrossresistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 104: 739–746.PubMedGoogle Scholar
  2. 2.
    Donohue JP, Einhorn LH, Williams SD (1980) Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 123: 876–880PubMedGoogle Scholar
  3. 3.
    Einhorn LH, Donohue JP (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293–298PubMedGoogle Scholar
  4. 4.
    Einhorn LH, Williams SD (1980) Chmotherapy of disseminated testicular cancer — a random prospective study. Cancer 46: 1339–1344PubMedCrossRefGoogle Scholar
  5. 5.
    Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, Shepherd A, Clark DA, Levitt M, MacDonald D, Wilson K, Shelley W, Pater J (1987) Superiority of alternating noncrossresistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107: 451–458PubMedGoogle Scholar
  6. 6.
    Goldie JH, Coldman AJ (1982) Rationale for the use of alternating noncrossresistant chemotherapy. Cancer Treat Rep 66: 439–449PubMedGoogle Scholar
  7. 7.
    Kuzmits R, Schernthaner G, Krisch K (1987) Serum neuron-specific enolase. A marker for response to therapy in seminoma. Cancer 60: 1017–1021PubMedCrossRefGoogle Scholar
  8. 8.
    Niederle N, Höffken K, Schütte J, Seeber S, Schmidt CG (1985) Ifosfamide / MESNA (IF/M) alone or in combination with etoposide (IF/M+E): Salvage therapy for patients with metastasized nonseminomatous testicular cancer (NSTC), Proc ASCO Vol 4: C-379Google Scholar
  9. 9.
    Peckham MJ (1981) Investigation and staging: General aspects and staging classification. In: Peckham MJ (ed) The management of testicular tumours. Edward Arnold, LondonGoogle Scholar
  10. 10.
    Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, McElwain TJ, Hendry WF (1983) The treatment of metastatic germ cell testicular tumours with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 47: 613–619PubMedCrossRefGoogle Scholar
  11. 11.
    Pugh RCB (1976) Testicular tumours — the panel classification. In: Pugh RCB (ed) Pathology of the testis. Blackwell Scientific Publications, LondonGoogle Scholar
  12. 12.
    Report from the Medical Research Council Working Party on Testicular Tumours: Prognostic factors in advanced nonseminomatous germ cell testicular tumours: results of a multicenter study (1985) Lancet i: 8–11Google Scholar
  13. 13.
    Samson MK, Fischer RL, Stephens RL, Rivkin S, Opipari M, Maloney T, Groppe C (1981) Vinblastine, bleomycin and cisdiamminedichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations — a SWOG study. Eur J Cancer 16: 1359–1366Google Scholar
  14. 14.
    Tiffany P, Morse MJ, Bosl G, Vaughan ED, Sogani PC, Herr HW, Whitmore WF (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 57: 978–983PubMedCrossRefGoogle Scholar
  15. 15.
    Trump DL, Horrvet L (1985) Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69: 259–261PubMedGoogle Scholar
  16. 16.
    Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28–34PubMedGoogle Scholar
  17. 17.
    Williams S, Einhorn L, Greco A, Birch R, Irwin L (1985) Disseminated germ cell tumors: A comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP-16 (BEP). Proc ASCO Vol 4: C-390Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. Kuzmits
  • H. Ludwig
  • P. Aiginger

There are no affiliations available

Personalised recommendations